Today it was announced that Thomas Tan has joined the Sound Bioventures team as a Principal. Thomas will identify new investment opportunities, conduct scientific and commercial due diligence, and participate in board work.
Prior to joining Sound Bioventures, Thomas was a senior principal at Lundbeckfonden Ventures, were he identified and managed investments, and was a board member at Atox Bio and VarmX. Prior to his position at Lundbeckfonden Ventures, he worked as a strategy consultant at LSD, Huron and Deallus advising biotech and pharma on portfolio strategy, product positioning and pricing. Before that Thomas started his own biotech company in Cambridge, UK.
Thomas received his postdoctoral training at University of Cambridge, UK after earning his D. Phil. in Medical Sciences from University of Oxford, UK, and his M.Sc. in Biochemistry from University of Copenhagen, DK.
Thomas will be based in the Copenhagen, Denmark, office.
Thomas Tan joins Sound Bioventures
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures Cambridge, MA, May 11, 2022 – Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T Cell-mediated pathologies, today announces the close of a $26 million fin ...
Thomas Tan joins Sound Bioventures
Today it was announced that Thomas Tan has joined the Sound Bioventures team as a Principal. Thomas will identify new investment opportunities, conduct scientific and commercial due diligence, and participate in board work. Prior to joining Sound Bioventures, Thomas was a senior principal at Lundbeckfonden Ventures, were he identified and managed i ...
Ester Sklarsky joins Sound Bioventures
Today we welcome Ester Sklarsky to the Sound Bioventures investment team as an Associate. Ester will manage our dealflow, identify new investment opportunities and conduct scientific and commercial due diligence. Ester joins us from Industrifonden where she made life science venture capital investments as an analyst as well as an associate. Ester a ...
Broad Media Coverage of the launch of Sound Bioventures Fund I
The launch of Sound Bioventures Fund I resulted in broad coverage of the international life science trade media and Scandinavian financial press. Our strategy to invest in clinical, or near clinical, private companies in niche/rare indications were well presented. As Bibhash put it in Biocentury “We’ll go to the best company in the spac ...